Neurocrine Biosciences Inc's Comment on Supply Chain
The company sources raw materials, active pharmaceutical ingredients (API), and other supplies for the production of INGREZZA, CRENESSITY, and product candidates from various third-party manufacturers and suppliers. Supply is maintained through long-term commercial supply and manufacturing agreements with multiple manufacturers. The company focuses on expanding and diversifying its third-party manufacturing relationships. It relies on third-party partners and quality system oversight to ensure compliance with current Good Manufacturing Practice (cGMP) requirements and applicable foreign standards.
Neurocrine Biosciences Inc's Comment on Supply Chain
The company sources raw materials, active pharmaceutical ingredients (API), and other supplies for the production of INGREZZA, CRENESSITY, and product candidates from various third-party manufacturers and suppliers. Supply is maintained through long-term commercial supply and manufacturing agreements with multiple manufacturers. The company focuses on expanding and diversifying its third-party manufacturing relationships. It relies on third-party partners and quality system oversight to ensure compliance with current Good Manufacturing Practice (cGMP) requirements and applicable foreign standards.
Sources:
Neurocrine Biosciences Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Neurocrine Biosciences Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
